Higher dose defibrotide for SOS after stem cell transplant
Treatments studied
Part of Digestive system, Heart & circulation clinical trials.
This study tests whether a higher dose of defibrotide can help patients who develop SOS/VOD after a stem cell transplant and haven't gotten better with the standard dose. SOS/VOD is a liver condition that sometimes also affects the kidneys or lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a bone marrow or stem cell transplant (autologous or allogeneic).
- You have been diagnosed with SOS (sinusoidal obstruction syndrome), also called VOD (veno-occlusive disease), along with kidney or lung problems.
- You have been treated with the standard dose of defibrotide (a drug to treat SOS) but are not improving, or are getting worse.
- You are 1 month to 75 years old.
- You are not on blood-thinning medications (except for minor uses like keeping IV lines open).
- You do not have any active bleeding (grade 2 or worse) and have not had a severe allergic reaction to defibrotide.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant from a half-matched donor using a strong conditioning regimen and a drug called defibrotide to protect organs. It aims to cure sickle cell disease in patients who have had serious complications like stroke, chest syndrome, or frequent pain episodes.
This trial studies whether an allogeneic (donor) stem cell transplant can help people with higher-risk myelofibrosis (fibrosis in the bone marrow). It looks at outcomes in different donor types as determined by matching rules and patient risk level.
This Phase 2 study tests an immune-suppressing treatment for people with sickle cell disease or beta-thalassemia who are preparing for a stem cell transplant from a donor. It aims to help the transplant work better by changing the immune response.
This Phase 2 trial tests whether an allogeneic stem cell transplant (from a donor) can treat VEXAS syndrome. It may help calm the body’s overactive inflammation and improve symptoms in eligible adults.
This trial tests whether giving high-flow oxygen can help treat a painful sickle cell “vaso-occlusive crisis” (VOC) and lower the risk of a serious lung complication. You may be eligible if you’re an adult with sickle cell disease experiencing an opioid-requiring pain flare and have higher risk for lung trouble.
This trial tests a sequence of treatments for SIOD (a genetic condition causing immune and kidney problems). First, you receive CD7 car-t cells, then a stem cell transplant from a family donor, followed by a kidney transplant from the same donor. The goal is to see if this approach is safe and can help your body accept the new kidney.
Hear when a new Sinusoidal Obstruction Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.